This draft guidance document for industry and FDA staff describes the Food and Drug Administration's proposed program to evaluate a globally harmonized alternative for premarket procedures. The program is intended to assess the feasibility of an internationally harmonized format and content for premarket submissions, e.g., premarket notification (510(k))submissions and premarket approval (PMA) applications. The following is a link to the complete set of documents.
http://www.fda.gov/cdrh/ode/guidance/1347.htmlFDA's proposed 'globally harmonized' PMA alternative
Jul 24, 2001
Latest in Regulatory
Recalls stable for radiation oncology tools despite tech advancements
September 18, 2026
FDA issues discussion paper on GenAI medical devices
August 18, 2026
Lantheus wins FDA approval for tau PET imaging agent
August 14, 2026



















